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2ABSTRACT
Background: No studies to date have demonstrated a clear association with breast cancer risk and
dietary exposure to acrylamide. We aimed to investigate this association in a large prospective
cohort of women.
Methods: A 217-item food frequency questionnaire was used to estimate dietary acrylamide intake
in 33 731 women aged 35-69 from the UK Women’s Cohort Study (UKWCS) followed up for a median
of 11 years.
Results: 1084 incident breast cancers occurred during follow-up. There was no evidence of an
overall association between acrylamide intake and breast cancer (hazard ratio = 1.08 per 10g/day,
95% CI: 0.98 to 1.18, Ptrend = 0.1). There was a suggestion of a possible weak positive association
between dietary acrylamide intake and pre-menopausal breast cancer after adjustment for potential
confounders (hazard ratio = 1.2, 95% CI: 1.0 to 1.3, Ptrend = 0.008). There was no suggestion of any
association for post-menopausal breast cancer (hazard ratio = 1.0, 95% CI: 0.9 to 1.1, Ptrend = 0.99).
Conclusions: There is no evidence of an association between dietary acrylamide intake and breast
cancer. A weak association may exist with pre-menopausal breast cancer, but this requires
confirmation in other studies. Given the widespread presence of acrylamide in food and the
relatively common nature of breast cancer, even a small association between the two could have
important public health implications.
Keywords: Cohort study; Acrylamide; Diet; Breast cancer
3BACKGROUND
Acrylamide is formed principally by the Maillard reaction between the amino acid asparagine and
reducing sugars such as glucose (Stadler et al., 2002). Until its discovery in high temperature cooked
carbohydrate-rich foods in 2002, it was thought that the main route of human exposure was
occupational or from smoking (Smith et al., 2001). The finding of significant amounts of acrylamide
in commonly consumed foods, such as potato crisps, French fries, coffee, biscuits and cold breakfast
cereal(Tareke et al., 2002), raised health concerns in light of its classification as a probable human
carcinogen by IARC(IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1994).
Animal studies have demonstrated that exposure to acrylamide causes a higher incidence of several
tumours, including those of the mammary gland, but at levels of intake much greater than the
equivalent typically observed in humans(Friedman, 2003;Besaratinia and Pfeifer, 2003;Rice,
2005;Spivey, 2010;Tardiff et al., 2010). As a consequence, several studies have attempted to assess
whether acrylamide exposure through foods increases cancer risk in humans.
Some evidence has been found of an association between dietary acrylamide and endometrial and
ovarian cancers (Hogervorst et al., 2007), but no studies to date have demonstrated a clear
association with breast cancer risk and dietary exposure to acrylamide(Mucci et al., 2005;Pelucchi et
al., 2006;Hogervorst et al., 2007;Larsson et al., 2009;Wilson et al., 2009a), apart from one study
suggesting a possible positive association with breast cancer among a subgroup of post-menopausal
never-smokers (Pedersen et al., 2010). In addition, a recent biomarker study found a possible
association with acrylamide-haemoglobin adduct levels for estrogen receptor positive post-
menopausal breast cancers, though there was no overall association for post-menopausal breast
cancers, and no investigation of pre-menopausal breast cancers.
We therefore aimed to investigate the association between dietary acrylamide intake and all breast
cancers in a large prospective cohort of women. The UK Women’s Cohort Study (UKWCS) is
participating in the NewGeneris consortium investigating dietary exposures to potentially
4carcinogenic compounds(Merlo et al., 2009) and is therefore ideally suited to investigating this
question.
MATERIALS AND METHODS
Subjects
The UKWCS is formed from a sample of 35 372 women who completed a 217-item Food Frequency
questionnaire (FFQ) between 1995 and 1998(Cade et al., 2004a). The Food Frequency Questionnaire
(FFQ) was based on the FFQ used in the UK arm of the European Prospective Investigation into
Cancer (EPIC) study which had been validated against 16-day weighed records and
biomarkers(Bingham et al., 1997), and adapted for this population in line with best practice(Cade et
al., 2004b) followed by further validation(Calvert et al., 1997;Buckley et al., 2001;Spence et al.,
2002). Subjects in the UKWCS are mainly white, affluent, well-educated women, and were initially
aged between 35 and 69 years. They are generally health conscious with only 11% current smokers
and 58% taking dietary supplements(Cade et al., 2004a). Physical activity levels and self-reported
weight, height and waist and hip circumferences were also collected at baseline. Ethical approval
was obtained from 174 local research ethics committees. Further details of the process have been
described previously(Cade et al., 2007;Taylor et al., 2007). The cohort was designed to include a
wide range of dietary patterns with similar large numbers of women consuming a vegetarian type
diet, women who ate fish but not meat and meat eaters. This approach ensures adequate power
whilst minimizing the effects of measurement error(Schatzkin et al., 2001;White et al., 1994;Kaaks
and Riboli, 1997).
5Acrylamide assessment
Estimated intakes of acrylamide were calculated for women participating in the UKWCS using the
frequencies of consumption of 24 food items reported in the FFQ that were potential sources of
dietary acrylamide, broadly grouped into potato chips, crisp breads, breakfast cereals, pastries and
bakery products, coffee, bread, biscuits, and potato crisps. Toast was not included as a separate item
in the FFQ, but was included as bread. Estimated acrylamide content was based on standard portion
sizes(Food Standards Agency, 2002) and European Union (EU) estimates of acrylamide content of
foods(European Commission Institute for Reference Materials and Measurements, 2006). The EU
database was set up to permit monitoring of acrylamide levels in food products throughout the
whole EU, which includes the UK. A recent validation study compared estimated acrylamide intake
based on average acrylamide levels of food items, such as those available in the EU database,
compared to chemically analyzed content(Konings et al., 2010). The correlation between chemically
determined acrylamide content and estimated acrylamide content was very high, indicating that
using single acrylamide values for individual foods based on average values of several available
samples such as that reported in the EU database results in a good rank ordering of most subjects,
despite the large variation of acrylamide concentrations within single foods. We further adapted the
database for the UK population by using coffee strengths and portion sizes based on those
appropriate for the UK(Food Standards Agency, 2002), and in addition we assumed that, for
exposure estimates in this population of middle-aged women, any potato chips consumed were
generally broader than the narrower French fries, and so with a relatively lower acrylamide content.
The FFQ was repeated in a random subsample of 1859 women five years after completion of the first
questionnaire. Spearman’s correlation was 0.61 for total dietary acrylamide intake, with similarly
high values across all dietary sources of acrylamide.
6Outcome assessment
Study participants were registered with the National Health Service Central Register so that all
incident cancer cases and deaths were notified to the study team. Incident cancers and cause of
death were coded according to the International Classification of Diseases 9 and 10. An incident
breast cancer was taken to be malignant breast cancer (ICD9 174, ICD10 C50) occurring after
completion of the FFQ. Breast cancer cases’ survival time was taken as date of completing the FFQ
until date of diagnosis. Non-cases’ survival was taken as being from date of enrolment until death or
end of follow-up (1st January 2008) whichever was the first. Menopausal status was coded using
specific criteria related to menstrual and obstetric history and age.
Statistical analysis
Cox’s proportional hazards regression was used to explore the relationship between estimated
dietary acrylamide intakes and risk of breast cancer using Stata version 11(StataCorp, 2009). Women
were excluded if they had extremely high (>6000kcal/day) or low (<500 kcal/day) reported total
energy intake, as were women with prevalent breast cancer. Associations were estimated for pre-
and post-menopausal women separately and combined, first as a simple model adjusting for age,
smoking status and amount smoked (model 1), and secondly as a full model additionally adjusting
for weight, height, physical activity (hours/day sufficiently vigorous to cause sweating), oral
contraceptive use, hormone replacement therapy use, parity, age at menarche, alcohol intake (as
grams of ethanol/day), energy intake other than from alcohol, and level of education (model 2).
Tests for trend were based on fitting the linear trend over the continuous measure of exposure.
To assess sensitivity of results to undiagnosed prevalent breast cancers at the time the FFQ was
completed, analyses were repeated after excluding any events occurring within 6 months of
completing the FFQ. A further analysis excluding current or ever smokers was undertaken as
7exposure to acrylamide through tobacco smoke inhalation is likely to be a more important source of
exposure than dietary sources alone(Olesen et al., 2008). For this subgroup there was no need to
adjust for smoking habits in the models. To investigate the sensitivity of results to including all bread
as untoasted, we assumed half of bread was toasted, with associated higher acrylamide content, and
re-ran all analyses.
RESULTS
The median follow up was 11 years, with 1084 incident breast cancers recorded. Using information
collected at baseline, 15 951 women were classified as being pre-menopausal and 17 779 post-
menopausal. Demographic and clinical characteristics of the study participants are shown in table 1
according to fifth of acrylamide intake (Table 1). The women with the highest dietary acrylamide
intakes were slightly younger, with higher body mass index, less physically active, less educated,
more likely to have children, have a higher total energy intake, have a lower alcohol intake, but more
likely to smoke.
[table 1 here]
Median dietary acrylamide intake was 15 µg/day (0.23 µg/kg/day), with an inter-quartile range of 10
to 21 µg/day (0.15 to 0.33 µg/kg/day). Only 316 / 33061 (1%) of women consumed more than 50
g/day of dietary acrylamide. Only 99 / 33061 (0.3%) of participants consumed in excess of 1
µg/kg/day, a threshold of intake cited by the World Health Organization in risk assessment
models(Joint Food and Agriculture Organization of the United Nations / World Health Organization
consultation on health implications of acrylamide in food, 2002), and still fewer exceed other
estimates of tolerable daily intake(Tardiff et al., 2010). The sources with greatest contribution to
8total dietary acrylamide intake in these middle-aged women in the United Kingdom were potato
chips (28% of intake), bakery goods (17%), potato crisps (14%), bread (10%), biscuits (9%), and coffee
(8%).
Overall, there was little evidence of an association between dietary acrylamide intake and breast
cancer when pre-menopausal and post-menopausal cancers were combined (hazard ratio = 1.08 per
10 g/day, 95% CI: 0.98 to 1.18, Ptrend = 0.1) (Table 2). However, there was evidence of a positive
dose-response association between dietary acrylamide intake and pre-menopausal breast cancer
after adjustment for potential confounders. Women in the highest fifth of dietary acrylamide intake
had approximately 50% higher risk of subsequent breast cancer than those in the lowest fifth
(hazard ratio = 1.47, 95% CI: 0.96 to 2.27) with associated risk increasing by approximately 20% with
every 10g/day increase in acrylamide intake (hazard ratio = 1.18, 95% CI: 1.05 to 1.34, Ptrend =
0.008). However, there was no such association for post-menopausal breast cancer (hazard ratio =
1.00, 95% CI: 0.88 to 1.14, Ptrend = 0.99), with similar numbers of pre-menopausal and post-
menopausal women offering similar power for each comparison.
[table 2 here]
These results were unchanged by excluding women with breast cancers diagnosed within 6 months
of completing the FFQ. When these analyses were further restricted to the subgroup of women who
had never smoked, the associations between dietary acrylamide and breast cancer were less
apparent, though power was much reduced (Table 3). If half of all recorded bread intake were as
toast, this would increase the median acrylamide intake to 20 g/day (inter-quartile range 14 to 27
g/day) or 0.31 g/kg/day (inter-quartile range 0.21 to 0.43 g/kg/day). However, dose-response
trends were very much the same as before.
9[table 3 here]
DISCUSSION
In our large UK cohort, we have shown no association between dietary acrylamide intake and
increased risk of breast cancer, either overall or for post-menopausal breast cancer, for modest
intakes consumed as part of a usual diet (<50g/day). However, there was some evidence for a
positive association with pre-menopausal breast cancer. There was a weak dose-response
relationship, but the association was particularly apparent in the highest fifth of dietary intake (>23
g/day).
Given that smoking is not a risk factor for breast cancer, and that smokers have substantially higher
levels of haemoglobin adducts of acrylamide and glycidamide than non-smokers(Bjellaas et al.,
2007;Hagmar et al., 2005), much higher than that associated with dietary intake, any association
between dietary intake and breast cancer is surprising. Given also that the acrylamide content of
tobacco outweighs any that of any dietary intake, it was also important to repeat the analyses
amongst a sub-group of never-smokers.
The association was less apparent in the subgroup of pre-menopausal women who had never
smoked. It is possible that the lack of a clear association amongst the never-smokers could be
explained by insufficient power to detect increased risk, as this subgroup comprises just a quarter of
the cohort. However, the overall number of cases of breast cancer reported in our cohort are
comparable to those in other major studies, such as the Nurses’ Health Study II(Wilson et al., 2009a),
which found no associations between intakes of acrylamide, or foods potentially high in acrylamide,
and invasive breast cancer.
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The FFQ used in our cohort is similar to that used in the European Prospective Investigation of
Cancer(Riboli and Kaaks, 1997) and follows recommendations for good design(Cade et al., 2004b).
However, no distinction was made between bread and toasted bread, which would have higher
acrylamide content. When the robustness of results was assessed by assuming a proportion of bread
was toasted, conclusions were unchanged.
Our average intakes were at the lower end of those previously reported from other
populations(Dybing and Sanner, 2003;Larsson et al., 2009;Svensson et al., 2003;Swiss Federal Office
of Public Health, 2002;US Food and Drug Administration, 2006;Wilson et al., 2009b). Partly this is an
artefact of presenting the more appropriate median intake, which is generally lower than the
mean(Dybing et al., 2005), and partly underestimation caused by grouping bread and toast together.
However, we believe these lower intakes also reflect the dietary habits of our middle-aged female
UK population who, at the time of completing the FFQ, consumed relatively fewer potato chips and
crisps, generally preferred tea rather than coffee, and consumed weaker coffee than some other
countries.
Our intakes are closer to those found in the US, Switzerland and the Netherlands, than to those
found in Scandinavia. For example, the proportion of acrylamide estimated to be from coffee in our
population (8%) is in keeping with figures from the Netherlands and US (Mucci & Wilson 2008), but
very different from the 39% reported in Sweden. The UKWCS participants generally have a health
conscious outlook with relatively low smoking rates and low body mass index(Cade et al., 2004a). It
is therefore possible that less healthy dietary patterns were under-represented in our cohort. This
may also have contributed to the relatively low daily intake of acrylamide in the UKWCS compared
to other studies.
Even in our relatively health-conscious cohort of middle-aged women, the main sources of
acrylamide were chips and crisps. It is therefore possible that any measure of dietary acrylamide
intake may be a proxy for poor diet, which could predict breast cancer. This in turn may be
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predictive of increased risk of breast cancer through other dietary risk factors such as higher fat or
processed meat intakes, for example(Bingham et al., 2003;Cade et al., 2007;Taylor et al., 2007).
Since this is a prospective study, recall bias is unlikely. However, it is possible that current estimates
of acrylamide content of food is incomplete, which may have lead to some misclassification of
exposure categories. In addition, estimates of acrylamide exposure were based on the responses to
one FFQ administered at recruitment into the cohort. Since the consumption of foods thought to be
contaminated with acrylamide may have changed over time, it is possible that our estimates of
exposure might have been improved with repeated dietary assessments. The range of acrylamide
levels reported for specific products, with different methods of preparation, is wide, and even within
brands considerable variation occurs between different batches(European Food Safety Authority,
2010). As the FFQ does not request brand-specific information, and individuals do not necessarily
remain loyal to one brand, this variation could not be accounted for in the exposure calculations. In
particular, the acrylamide content of coffee will differ by brand and strength of coffee
consumed(Bagdonaite et al., 2008). This choice varies considerably between individuals, and across
different countries. However, studies have shown that it is possible for FFQs to estimate dietary
acrylamide intake well(Dybing et al., 2005;Brantsaeter et al., 2008).
[table 4 here]
Table 4 briefly summaries the results from some existing studies of dietary acrylamide and breast
cancer. The majority of studies, like ours, found no evidence of an association between dietary
acrylamide intake and incident breast cancer, at least within the range of intakes studied. The
Netherlands Cohort study only found indications of a positive association between dietary
acrylamide intake and a subgroup of hormone receptor-positive breast cancers in postmenopausal
women who have never smoked(Hogervorst et al., 2007;Pedersen et al., 2010), and recognised that
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further studies were required to confirm or refute this. However, there is other evidence that
acrylamide may interfere with hormone systems(Hogervorst et al., 2010). A weakness of our study
was that we did not have information on hormone receptor status and so we were unable to
selectively report results by tumour receptor positivity.
The strongest suggestion of a positive association comes from a large prospective cohort(Olesen et
al., 2008), where the association between breast cancer and biomarkers for acrylamide exposure
was assessed using haemoglobin adduct levels, as well as glycidamide, which is the genotoxic
metabolite of acrylamide. After adjustment for smoking behaviour in their nested case-control
study, a positive association was seen between acrylamide-haemoglobin adduct levels and
oestrogen receptor positive breast cancer. Our study takes this further and relates breast cancer
directly to the original dietary consumption that may contribute to the adduct levels and metabolite
concentrations. A recent cross-sectional analysis of individuals found higher biomarker values of
acrylamide in the United Kingdom than in other European countries(Vesper et al., 2008), suggesting
that this may be of particular importance in the United Kingdom, and a possible explanation for any
differences between our results and those from other countries.
There is some mechanistic evidence to support this epidemiological evidence. In animal studies,
acrylamide is causally associated with mammary tumour development(Johnson et al.,
1986;Friedman et al., 1995;Rice, 2005;Wilson et al., 2009a), but to date there has been less evidence
that acrylamide consumption at levels typically observed in normal diets is related to human breast
cancer risk. The typical acrylamide intake of women in our study is substantially lower than the dose
levels that have been found to cause effects in these animal studies.
Given the widespread presence of acrylamide in food and the relatively common nature of breast
cancer, even a small association between the two would have important public health implications.
In the first study reporting on a UK population we have shown no overall association between
dietary acrylamide intake and breast cancer risk but a weak positive association was observed for
13
women with the distinct clinical and pathological subset of pre-menopausal breast cancers. With
these results, and other studies suggesting an association with tumour hormone-receptor status,
further investigation is needed to explore potential interactions with hormone levels and
mechanistic pathways.
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Table 1. Demographic and clinical characteristics of women in the UKWCS by fifth of intake of
acrylamide.
Acrylamide intake
Fifth 1 2 3 4 5
Mean (g/day) 6 11 15 20 32
Range (g/day) 0 to 9 9 to 13 13 to 17 17 to 23 23 to 150
Mean age (years) (SD) 52.8 (9.2) 52.7 (9.1) 52.5 (9.3) 51.6 (9.3) 51.4 (9.5)
Mean BMI (kg/m2) (SD) 24.0 (4.2) 24.5 (4.4) 24.4 (4.1) 24.6 (4.6) 24.8 (4.5)
Mean physical Activity
(hours/day) (SD) 0.3 (0.5) 0.3 (0.5) 0.3 (0.5) 0.2 (0.4) 0.2 (0.5)
Mean age at menarche
(years) (SD) 12.8 (1.7) 12.8 (1.6) 12.8 (1.6) 12.8 (1.6) 12.9 (1.6)
Current HRT use (%) 1336 (20%) 1386 (21%) 1348 (20%) 1239 (19%) 1206 (18%)
Current OCP use (%) 251 (4%) 232 (3%) 278 (4%) 264 (4%) 266 (4%)
Nulliparous (%) 1954 (29%) 1614 (24%) 1394 (21%) 1346 (20%) 1240 (18%)
Postmenopause (%) 3776 (56%) 3716 (55%) 3620 (54%) 3360 (50%) 3300 (49%)
Incident breast cancer
(%) 220 (3%) 213 (3%) 219 (3%) 211 (3%) 218 (3%)
Mean total energy
intake (MJ) (SD) 8.0 (2.4) 8.9 (2.4) 9.6 (2.4) 10.4 (2.6) 12.1 (3.3)
Mean ethanol intake
(g/day) (SD) 9.0 (11.4) 9.1 (10.5) 8.7 (10.6) 8.5 (10.1) 8.0 (10.1)
Current smoker (%) 684 (11%) 682 (10%) 710 (11%) 718 (11%) 846 (13%)
15
No education >14years
(%) 840 (14%) 951 (15%) 1038 (17%) 1076 (17%) 1291 (21%)
16
Table 2. Hazard ratios of pre- and post-menopausal breast cancer according to acrylamide intake for all participants.
Model 1* Model 2**
Fifth of acrylamide
intake
Range
(g/day)
cases / total HR 95% CI Ptrend
***
HR 95% CI Ptrend
***
All breast cancers
1 0 – 9 220 / 6747 1.00 - 1.00 -
2 9 – 13 213 / 6748 0.92 (0.74, 1.13) 1.06 (0.83, 1.35)
3 13 – 17 219 / 6747 0.90 (0.73, 1.11) 1.05 (0.82, 1.34)
4 17 – 23 211 / 6748 0.92 (0.75, 1.14) 1.12 (0.87, 1.45)
5 23 – 150 218 / 6748 0.97 (0.79, 1.19) 1.16 (0.88, 1.52)
Trend (per 10 g/day) 0.99 (0.92, 1.06) Ptrend = 0.7 1.08 (0.98, 1.18) Ptrend = 0.1
Pre-menopausal
1 0 – 9 73 / 2956 1.00 - 1.00 -
2 9 – 13 85 / 3032 1.03 (0.7, 1.5) 1.06 (0.71, 1.59)
3 13 – 17 88 / 3127 1.01 (0.7, 1.4) 1.15 (0.77, 1.71)
4 17 – 23 90 / 3388 0.95 (0.7, 1.3) 1.15 (0.76, 1.73)
5 23 – 150 102 / 3448 1.20 (0.9, 1.7) 1.47 (0.96, 2.27)
Trend (per 10 g/day) 1.06 (0.96, 1.17) Ptrend = 0.2 1.18 (1.05, 1.34) Ptrend = 0.008
Post-menopausal
1 0 – 9 135 / 3776 1.00 - 1.00 -
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2 9 – 13 128 / 3716 0.96 (0.7, 1.2) 1.06 (0.78, 1.44)
3 13 – 17 131 / 3620 0.95 (0.7, 1.2) 1.00 (0.73, 1.38)
4 17 – 23 121 / 3360 1.03 (0.8, 1.3) 1.14 (0.82, 1.58)
5 23 – 150 116 / 3300 0.97 (0.7, 1.3) 0.97 (0.68, 1.39)
Trend (per 10 g/day) 0.98 (0.90, 1.07) Ptrend = 0.7 1.00 (0.88, 1.14) Ptrend = 0.99
* Model 1 is adjusted for age.
** Model 2 is also adjusted for smoking status and amount smoked weight, height, physical activity (hours/day sufficiently vigorous to cause sweating), oral
contraceptive use, hormone replacement therapy use, parity, age at menarche, alcohol intake (as grams of ethanol/day), energy intake other than from
alcohol, and level of education.
*** P-value for trend is based on fitting the linear trend over the continuous exposure.
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Table 3. Hazard ratios of pre- and post-menopausal breast cancer according to acrylamide intake for women who have never smoked.
Model 1* Model 2**
Fifth of acrylamide
intake
Range
(g/day)
cases / total HR 95% CI Ptrend*** HR 95% CI Ptrend***
All breast cancers
1 0 – 9 128 / 3584 1.00 - 1.00 -
2 9 – 13 114 / 3745 0.78 (0.60, 1.03) 0.87 (0.63, 1.20)
3 13 – 17 130 / 3847 0.82 (0.63, 1.07) 0.95 (0.69, 1.30)
4 17 – 23 120 / 3885 0.79 (0.60, 1.03) 0.96 (0.69, 1.34)
5 23 – 150 115 / 3841 0.82 (0.62, 1.07) 0.98 (0.69, 1.40)
Trend (per 10 g/day) 0.94 (0.85, 1.04) Ptrend = 0.2 1.06 (0.93, 1.21) Ptrend = 0.4
Pre-menopausal
1 0 – 9 45 / 1604 1.00 - 1.00 -
2 9 – 13 38 / 1709 0.73 (0.45, 1.19) 0.68 (0.39, 1.20)
3 13 – 17 59 / 1805 1.04 (0.68, 1.61) 1.12 (0.69, 1.83)
4 17 – 23 54 / 1990 0.80 (0.51, 1.25) 0.98 (0.59, 1.62)
5 23 – 150 57 / 2024 1.00 (0.65, 1.54) 1.17 (0.69, 2.00)
Trend (per 10 g/day) 1.01 (0.88, 1.15) Ptrend = 0.9 1.13 (0.95, 1.33) Ptrend = 0.2
Post-menopausal
1 0 – 9 76 / 1972 1.00 - 1.00 -
2 9 – 13 76 / 2036 0.89 (0.64, 1.26) 0.98 (0.66, 1.46)
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3 13 – 17 71 / 2042 0.79 (0.56, 1.13) 0.83 (0.54, 1.26)
4 17 – 23 66 / 1895 0.89 (0.63, 1.25) 0.99 (0.64, 1.53)
5 23 – 150 58 / 1817 0.81 (0.57, 1.16) 0.86 (0.53, 1.37)
Trend (per 10 g/day) 0.95 (0.83, 1.08) Ptrend = 0.4 1.01 (0.83, 1.24) Ptrend = 0.9
* Model 1 is adjusted for age.
** Model 2 is also adjusted for smoking status and amount smoked weight, height, physical activity (hours/day sufficiently vigorous to cause sweating), oral
contraceptive use, hormone replacement therapy use, parity, age at menarche, alcohol intake (as grams of ethanol/day), energy intake other than from
alcohol, and level of education.
*** P-value for trend is based on fitting the linear trend over the continuous exposure.
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Table 4. A brief summary of some existing prospective studies of dietary acrylamide and breast cancer incidence in humans.
Study Population Dietary acrylamide intake Main findings
RR (95% confidence interval)
Women’s Lifestyle and Health
Cohort (Mucci et al., 2005)
Cohort of 43 404 women in Sweden, mean age
39, 91% premenopausal, with 667 incident cases.
Measured by 98-item
FFQ.
RR (highest:lowest fifth) = 1.19 (0.91,
1.55)
The Italian multicentre case-
control study of breast cancer
(Pelucchi et al., 2006)
Hospital-based case-control study in Italy and
Switzerland between 1991 and 2001 with 2900
cases and 3122 controls.
Measured by 78-item
FFQ.
RR (highest:lowest fifth) = 1.06 (0.88,
1.28)
The Danish Diet, Cancer and
Health study (Olesen et al., 2008)
Case-control nested with a cohort of 24 697
postmenopausal women in Denmark, aged 50 to
64, with 374 incident cases.
Haemoglobin adducts of
acrylamide.
Per 10-fold increase in acrylamide
adducts, RR = 1.05 (0.66, 1.69); RR = 2.7
(1.1, 6.6) for ER+.
The Swedish Mammography
Cohort (Larsson et al., 2009)
Cohort of 61 433 women attending
mammography in Sweden, aged 42 to 72, with
2952 incident cases.
Measured by 67-item and
96-item FFQs.
RR (highest:lowest quarter) = 0.91
(0.80, 1.02); 0.89 (95% CI: 0.74, 1.08) for
ER+PR+; 1.17 (95% CI: 0.84, 1.64) for
ER+PR-; 0.91 (95% CI: 0.61, 1.38) for ER-
PR-.
Nurses’ Health Study II (Wilson et
al., 2009a)
Cohort of 90 628 premenopausal women
completing an FFQ in 1991, aged 27 to 44, with
1179 incident cases.
Measured by 130-item
FFQ.
RR (highest:lowest fifth) = 0.92 (0.76,
1.11); 1.31 (0.87, 1.97) for ER+; 1.47
(0.86, 2.51) for PR+; 1.43 (0.83, 2.46) for
ER+PR+.
The Netherlands Cohort
(Hogervorst et al., 2007;Pedersen
Case-cohort analysis nested within a cohort of 62
573 postmenopausal women in the Netherlands,
Measured by 150-item
FFQ.
RR (highest:lowest fifth) = 0.92 (0.73,
1.15)
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et al., 2010) aged 55 to 69, with 2225 incident cases.
The United Kingdom Women’s
Cohort study (Burley et al., 2010)
Cohort of 33 731 women in the United Kingdom,
aged 35 to 69, 47% premenopausal, with 1084
incident cases.
Measured by 217-item
FFQ.
RR (highest:lowest fifth) = 1.16 (0.88,
1.52); 1.47 (0.96, 2.27) for
premenopausal; 0.97 (0.88, 1.14) for
postmenopausal.
Abbreviations: ER+ = estrogen receptor positive breast cancers; PR+ = progesterone receptor positive breast cancers
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